134 related articles for article (PubMed ID: 2702064)
21. 6-mercaptopurine plasma levels in children with acute lymphoblastic leukemia: relation to relapse risk and myelotoxicity.
Hayder S; Lafolie P; Björk O; Peterson C
Ther Drug Monit; 1989 Nov; 11(6):617-22. PubMed ID: 2595740
[TBL] [Abstract][Full Text] [Related]
22. Large interindividual variations in the pharmacokinetics of oral 6-mercaptopurine in maintenance therapy of children with acute leukaemia and non-Hodgkin lymphoma.
Lafolie P; Hayder S; Björk O; Ahström L; Liliemark J; Peterson C
Acta Paediatr Scand; 1986 Sep; 75(5):797-803. PubMed ID: 3564948
[TBL] [Abstract][Full Text] [Related]
23. The effect of methotrexate on the bioavailability of oral 6-mercaptopurine.
Balis FM; Holcenberg JS; Zimm S; Tubergen D; Collins JM; Murphy RF; Gilchrist GS; Hammond D; Poplack DG
Clin Pharmacol Ther; 1987 Apr; 41(4):384-7. PubMed ID: 3470165
[TBL] [Abstract][Full Text] [Related]
24. [Pharmacokinetics of 6-mercaptopurine in children with acute lymphoblastic leukemia--interindividual and intraindividual variations].
Hijiya N; Kato Y; Matsushita T; Yokoyama T
Rinsho Ketsueki; 1989 Nov; 30(11):1931-6. PubMed ID: 2607612
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetics of oral 6-mercaptopurine: relationship between plasma levels and urine excretion of parent drug.
Endresen L; Lie SO; Storm-Mathisen I; Rugstad HE; Stokke O
Ther Drug Monit; 1990 May; 12(3):227-34. PubMed ID: 2349605
[TBL] [Abstract][Full Text] [Related]
26. Preparation, Characterization, Pharmacokinetic, and Therapeutic Potential of Novel 6-Mercaptopurine-Loaded Oral Nanomedicines for Acute Lymphoblastic Leukemia.
Zou Y; Mei D; Yuan J; Han J; Xu J; Sun N; He H; Yang C; Zhao L
Int J Nanomedicine; 2021; 16():1127-1141. PubMed ID: 33603372
[TBL] [Abstract][Full Text] [Related]
27. A phase II trial of continuous-infusion 6-mercaptopurine for childhood leukemia.
Adamson PC; Zimm S; Ragab AH; Balis F; Steinberg SM; Kamen BA; Vietti TJ; Gillespie A; Poplack DG
Cancer Chemother Pharmacol; 1992; 30(2):155-7. PubMed ID: 1600597
[TBL] [Abstract][Full Text] [Related]
28. Why more 6-mercaptopurine?
Kamen BA
Semin Hematol; 1991 Jul; 28(3 Suppl 4):12-4. PubMed ID: 1780746
[No Abstract] [Full Text] [Related]
29. Profile of non-compliance in lymphoblastic leukaemia.
Lancaster D; Lennard L; Lilleyman JS
Arch Dis Child; 1997 Apr; 76(4):365-6. PubMed ID: 9166035
[TBL] [Abstract][Full Text] [Related]
30. Cranial irradiation and cerebrospinal fluid levels of 6-mercaptopurine in children with acute leukemia.
Riccardi R; Lasorella A; Tartaglia RL; Riccardi A; Servidei T; Mastrangelo R
Med Oncol Tumor Pharmacother; 1991; 8(2):95-8. PubMed ID: 1749306
[TBL] [Abstract][Full Text] [Related]
31. Determination of 6-mercaptopurine in acute lymphoblastic leukemia patients' plasma by high-performance liquid chromatography.
Kato Y; Matsushita T; Yokoyama T; Mohri K
Ther Drug Monit; 1991 May; 13(3):220-5. PubMed ID: 1926275
[TBL] [Abstract][Full Text] [Related]
32. The pharmacology of orally administered chemotherapy. A reappraisal.
Poplack DG; Balis FM; Zimm S
Cancer; 1986 Jul; 58(2 Suppl):473-80. PubMed ID: 3459570
[TBL] [Abstract][Full Text] [Related]
33. 6-Thioguanine in children with acute lymphoblastic leukaemia: influence of food on parent drug pharmacokinetics and 6-thioguanine nucleotide concentrations.
Lancaster DL; Patel N; Lennard L; Lilleyman JS
Br J Clin Pharmacol; 2001 Jun; 51(6):531-9. PubMed ID: 11422012
[TBL] [Abstract][Full Text] [Related]
34. Compliance with oral chemotherapy in childhood lymphoblastic leukaemia.
Davies HA; Lilleyman JS
Cancer Treat Rev; 1995 Mar; 21(2):93-103. PubMed ID: 7758006
[No Abstract] [Full Text] [Related]
35. Possible implication of thiopurine S-methyltransferase in occurrence of infectious episodes during maintenance therapy for childhood lymphoblastic leukemia with mercaptopurine.
Dervieux T; Médard Y; Verpillat P; Guigonis V; Duval M; Lescoeur B; Suciu S; Vilmer E; Jacqz-Aigrain E
Leukemia; 2001 Nov; 15(11):1706-12. PubMed ID: 11681411
[TBL] [Abstract][Full Text] [Related]
36. 6-Mercaptopurine in cerebrospinal fluid during oral maintenance therapy of children with acute lymphoblastic leukemia.
Hayder S; Lafolie P; Björk O; Ahström L; Peterson C
Med Oncol Tumor Pharmacother; 1988; 5(3):187-9. PubMed ID: 3166086
[TBL] [Abstract][Full Text] [Related]
37. Impact of morning versus evening schedule for oral methotrexate and 6-mercaptopurine on relapse risk for children with acute lymphoblastic leukemia. Nordic Society for Pediatric Hematology and Oncology (NOPHO).
Schmiegelow K; Glomstein A; Kristinsson J; Salmi T; Schrøder H; Björk O
J Pediatr Hematol Oncol; 1997; 19(2):102-9. PubMed ID: 9149738
[TBL] [Abstract][Full Text] [Related]
38. A comparison of red blood cell thiopurine metabolites in children with acute lymphoblastic leukemia who received oral mercaptopurine twice daily or once daily: a Pediatric Oncology Group study (now The Children's Oncology Group).
Bell BA; Brockway GN; Shuster JJ; Erdmann G; Sterikoff S; Bostrom B; Camitta BM;
Pediatr Blood Cancer; 2004 Aug; 43(2):105-9. PubMed ID: 15236274
[TBL] [Abstract][Full Text] [Related]
39. Gene expression and thioguanine nucleotide disposition in acute lymphoblastic leukemia after in vivo mercaptopurine treatment.
Zaza G; Cheok M; Yang W; Panetta JC; Pui CH; Relling MV; Evans WE
Blood; 2005 Sep; 106(5):1778-85. PubMed ID: 15905191
[TBL] [Abstract][Full Text] [Related]
40. Disposition of oral methotrexate in children with acute lymphoblastic leukemia and its relation to 6-mercaptopurine pharmacokinetics.
Koren G; Solh H; Klein J; Soldin SJ; Greenberg M
Med Pediatr Oncol; 1989; 17(6):450-4. PubMed ID: 2586358
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
